ReviewEmerging infectious diseases2022
Extensively Drug-Resistant Carbapenemase-Producing Pseudomonas aeruginosa and Medical Tourism from the United States to Mexico, 2018-2019.
Review in Emerging infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Global prevalence and antibiotic resistance profiles of carbapenem-resistantFrontiers in microbiology · 2025Pooled it
- Integron architecture and virulence-associated gene profiles in extensively drug-resistant high-riskFrontiers in microbiology · 2026Article
- Broad-Spectrum Protective Efficacy of a Fully Human Antibody Cocktail Targeting PcrV, ETA, and PA0833 AgainstInfection and drug resistance · 2026Article
- Mending a World of Problems: 12-Year Review of Medical Tourism Inbound Complications in a Tertiary Centre.Aesthetic plastic surgery · 2025Article
- Unveiling a hidden threat: whole genome sequencing exposes the cross-hospital spread of extensively drug-resistantFrontiers in microbiology · 2025Article
- Tracing the origin of NDM-1-producing and extensively drug-resistant Pseudomonas aeruginosa ST357 in the Netherlands.BMC infectious diseases · 2024Article
- Extensively Drug-Resistant Pseudomonas aeruginosa Outbreak Associated With Artificial Tears.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- In vitro activity of cefiderocol against a global collection of carbapenem-resistant Pseudomonas aeruginosa with a high level of carbapenemase diversity.The Journal of antimicrobial chemotherapy · 2024Article
- Healthcare seeking during travel: an analysis by the GeoSentinel surveillance network of travel medicine providers.Journal of travel medicine · 2023Article
- Antibiotic susceptibility pattern, risk factors, and prediction of carbapenem-resistantHeliyon · 2023Article
- Development and Evaluation of Bacteriophage Cocktail to Eradicate Biofilms Formed by an Extensively Drug-Resistant (XDR)Viruses · 2023Article
- Effects of Broad-Spectrum Antibiotic (Florfenicol) on Resistance Genes and Bacterial Community Structure of Water and Sediments in an Aquatic Microcosm Model.Antibiotics (Basel, Switzerland) · 2022Article
- Whole-Genome Sequencing Reveals Diversity of Carbapenem-ResistantAntimicrobial agents and chemotherapy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 9 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbapenem-resistant Pseudomonas aeruginosa (CRPA) producing the Verona integron‒encoded metallo-β-lactamase (VIM) are highly antimicrobial drug-resistant pathogens that are uncommon in the United States. We investigated the source of VIM-CRPA among US medical tourists who underwent bariatric surgery in Tijuana, Mexico. Cases were defined as isolation of VIM-CRPA or CRPA from a patient who had an elective invasive medical procedure in Mexico during January 2018‒December 2019 and within 45 days before specimen collection. Whole-genome sequencing of isolates was performed. Thirty-eight case-patients were identified in 18 states; 31 were operated on by surgeon 1, most frequently at facility A (27/31 patients). Whole-genome sequencing identified isolates linked to surgeon 1 were closely related and distinct from isolates linked to other surgeons in Tijuana. Facility A closed in March 2019. US patients and providers should acknowledge the risk for colonization or infection after medical tourism with highly drug-resistant pathogens uncommon in the United States.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.